

8<sup>th</sup> May 2013

Dear Healthcare Professional,

**Re: WOCKHARDT Morphine Sulphate Injection 10mg/1mL**

This is an update to the previous communication sent on 10 April 2013 reminding healthcare professionals of the differences between the **WOCKHARDT** Morphine Sulphate 10mg/ml and the DBL™ Morphine Sulfate injection BP products.

Hospira wish to advise healthcare professionals that when administering **WOCKHARDT Morphine Sulphate Solution for Injection**, to refer to the current approved United Kingdom (UK), Summary of Product Characteristics (SPC), which is included in the pack with the product. The SPC provides prescribing information and full details regarding the approved and recommended use of the Wockhardt product. The SPC can also be obtained via the following link:

<http://medicines.org.uk/emc/medicine/13143/SPC/Morphine+Sulphate+10mg+ml+Injection+BP/>

WOCKHARDT Morphine Sulphate 10mg/1mL contains preservative and therefore CANNOT be used for epidural or intrathecal administration. Furthermore, this product is only licensed for use in adults and only for subcutaneous, intramuscular and intravenous injection use.

Use of this product outside the approved indications and beyond the details provided in the SPC is not endorsed by Wockhardt UK Limited, the Marketing Authorisation Holder in the United Kingdom.

If you have any queries regarding this matter please contact us on the below details.

<b>Hospira Customer Service</b>	1300 046 774 – Option 1 <a href="mailto:CustomerService.au@hospira.com">CustomerService.au@hospira.com</a>	Customer Support including product availability
<b>Medical Information Team</b>	1300 046 774 – Option 2 or <a href="mailto:MedicalInformationAUS@hospira.com">MedicalInformationAUS@hospira.com</a>	Medical enquiries

Kind Regards,

Charles O'Sullivan  
Director of Medical Affairs, Asia Pacific  
Hospira Pty Ltd